Neurosense Therapeutics Ltd NRSN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 4:00 PM EDT
1.29quote price arrow up+0.02 (+1.57%)
Volume
231,069
52 week range
0.40 - 2.33
Loading...
  • Open1.20
  • Day High1.49
  • Day Low1.20
  • Prev Close1.27
  • 52 Week High2.33
  • 52 Week High Date03/01/24
  • 52 Week Low0.40
  • 52 Week Low Date10/24/23

Key Stats

  • Market Cap22.361M
  • Shares Out17.33M
  • 10 Day Average Volume0.08M
  • Dividend-
  • Dividend Yield-
  • Beta1.71
  • YTD % Change64.33

KEY STATS

  • Open1.20
  • Day High1.49
  • Day Low1.20
  • Prev Close1.27
  • 52 Week High2.33
  • 52 Week High Date03/01/24
  • 52 Week Low0.40
  • 52 Week Low Date10/24/23
  • Market Cap22.361M
  • Shares Out17.33M
  • 10 Day Average Volume0.08M
  • Dividend-
  • Dividend Yield-
  • Beta1.71
  • YTD % Change64.33

RATIOS/PROFITABILITY

  • EPS (TTM)-0.76
  • P/E (TTM)-1.69
  • Fwd P/E (NTM)-1.50
  • EBITDA (TTM)-13.302M
  • ROE (TTM)-602.40%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-3.90%

EVENTS

  • Earnings Date05/25/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Neurosense Therapeutics Ltd

 

Profile

MORE
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in...
Mark Leuchtenberger
Independent Non-Executive Chairman of the Board
Alon Ben-Noon
Chief Executive Officer, Director
Or Eisenberg
Chief Financial Officer
Address
11 Hamenofim St., Building B
Herzliya
4672562
Israel